Developer docs
API playgroundTry for free, no card

Search company profiles

IVF 2.0

Full company profile

uuid002l9lb

Namestring
IVF 2.0
Legal namestring
IVF 2.0
Websiteurl
ivf20.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

IVF 2.0 is a UK-based, privately held embryology innovation organization founded in 2018 by internationally recognized embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. The company builds AI-driven software for fertility clinics, with two core products: SiD (Sperm Identification Device), which uses computer vision to analyze sperm samples and identify optimal cells for IVF procedures, and ERICA (Embryo Ranking Intelligent Classification Assistant), which applies predictive analytics to embryo imaging data to rank and classify embryos for embryologist decision support. Both systems are trained in part on Indian genome sequencing data to localize model precision for Indian patient populations. The company serves a single vertical — IVF clinics and fertility centers — and goes to market as a B2B technology provider rather than a direct-to-patient offering.

IVF 2.0's business model centers on technology licensing or integration with fertility clinic networks. In April 2026, the company entered the Indian market through a flagship partnership with Gaudium IVF and Women Health Ltd, integrating SiD and ERICA into clinical practice as India's first AI-driven infertility treatment program; the launch was inaugurated by Union Minister Nitin Jairam Gadkari. Early clinical observations from this deployment are reported as a 58% first-attempt clinical pregnancy success rate, up to 15% improvement in fertilisation and blastocyst development rates versus standard methods, and a potential 5–7% improvement in first-cycle IVF success rates. The India IVF market is projected to grow from USD 900 million in 2024 to USD 1.87 billion by 2029 at ~15.8% CAGR, providing the company's primary growth runway.

The company operates with 1–10 employees from London and has not publicly disclosed pricing, revenue, or funding rounds. Its near-term commercial profile is concentrated on a single named enterprise customer (Gaudium IVF), creating significant customer concentration risk. With two purpose-built AI products, a credible founder talent base, and a regionally differentiated data approach, IVF 2.0 sits in an early commercialization phase focused on establishing clinical validation and recurring clinic relationships in India before broader geographic or segment expansion.

Short descriptiontext

IVF 2.0 is a UK-based AI software company that builds computer vision and predictive analytics tools — SiD for sperm selection and ERICA for embryo ranking — for IVF clinics. It serves fertility centers, with its flagship deployment at India's Gaudium IVF chain.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
AI embryology tools, IVF success optimization, embryo ranking software, sperm identification systems, fertility clinic AI
Industry4 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYHDAEANAJ
AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
NAICS code2 codes
  • Software Publishers5132
  • Computer Systems Design Services541512
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI-Assisted Reproductive Technology
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

IVF 2.0 develops AI-driven embryology software for IVF clinics and fertility centers. Its two core products, SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), use computer vision and predictive analytics to optimize sperm selection and embryo ranking, with the aim of improving fertilisation, blastocyst development, and overall IVF success rates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 15% improvement in fertilisation and blastocyst development rates compared to standard methods
+2 more records
Product overview1 text field

IVF 2.0 is a UK-based embryology innovation organization founded by embryologists Dr. Jacques Cohen and Dr. Alejandro Chave, offering a portfolio of AI-driven embryology tools designed to improve IVF outcomes. The core offerings consist of two integrated AI systems: SiD (Sperm Identification Device) for sperm selection and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo ranking. These tools work together as part of a precision-led approach to infertility treatment, leveraging computer vision and predictive analytics to reduce the emotional and financial burden on patients while improving fertilisation and blastocyst development rates.

Product and service2 records
1SiD (Sperm Identification Device)
CategoryAI-Assisted Reproductive Technology
Description

An AI-driven sperm identification system that uses computer vision to analyze and select optimal sperm cells for IVF procedures, designed to improve precision in infertility treatment and fertilisation outcomes for IVF clinics and embryologists.

2ERICA (Embryo Ranking Intelligent Classification Assistant)
CategoryAI-Assisted Reproductive Technology
Description

An AI-powered embryo ranking platform that analyzes embryo visual characteristics and developmental potential to classify and rank embryos, helping clinicians select the most viable embryos for transfer and potentially increasing IVF success rates for fertility centers.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

IVF 2.0 partnered with Gaudium IVF to introduce AI-led embryology tools including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) into clinical practice. The initiative, inaugurated by Union Minister Nitin Jairam Gadkari, marks India's first AI-driven infertility treatment program. Early clinical observations indicate improved fertilisation rates and blastocyst development rates. The technology aims to improve outcomes while reducing emotional, physical, and financial burden on patients.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Fairtility
TypeDirect peer
Description

Fairtility offers an AI-based embryo quality assessment platform (CHLOE) used by IVF clinics for transparent, data-driven embryo selection. It directly competes with IVF 2.0's ERICA in the AI embryo-ranking category.

TypeBroad incumbent
Description

Vitrolife is a global provider of IVF media, consumables, and increasingly AI-enabled tools (via Life Whisperer). It is a broad incumbent in fertility whose portfolio overlaps with IVF 2.0's clinical decision support.

TypeBroad incumbent
Description

CooperSurgical is a major provider of fertility and women's health products, including IVF lab equipment and media. As a broad incumbent with deep clinic relationships, it represents both a competitive threat and a potential exit partner for IVF 2.0.

TypeBroad incumbent
Description

Genea Biomedx develops IVF lab devices and software (e.g., Geri time-lapse incubator, Gems embryo culture). It is an incumbent in AI-enabled embryo monitoring and a relevant comparability anchor for IVF 2.0's clinical tooling.

TypeBroad incumbent
Description

Hamilton Thorne provides precision instruments, image-based systems, and AI/disposable products for the IVF and reproductive research markets. It is a broad incumbent whose imaging and analysis systems compete with IVF 2.0's computer-vision approach.

TypeDirect peer
Description

Alife Health applies AI to fertility treatment decision support, including embryo selection and IVF cycle optimization. It is a direct peer addressing the same clinical pain points (sperm/embryo selection precision) with an AI software model.

7Presagen
TypeDirect peer
Description

Presagen builds AI healthcare products with a focus on women's health and fertility, including embryo and oocyte assessment. It overlaps with IVF 2.0 in applying AI to reproductive medicine workflows.

TypeDirect peer
Description

AIVF develops AI-based clinical decision support for IVF clinics, including embryo evaluation tools. It is the closest direct competitor to IVF 2.0's SiD and ERICA offerings, serving the same fertility clinic customer base with computer-vision-driven IVF optimization.

TypeDirect peer
Description

Life Whisperer provides AI-based embryo and sperm viability assessment, now part of Vitrolife. It is a direct competitor to IVF 2.0 in AI-driven gamete and embryo selection.

TypeEmerging player
Description

Univfy uses predictive analytics to provide personalized IVF success probability reports, helping clinics with patient counseling. It is an emerging player in AI for IVF decision support with adjacent rather than direct overlap to IVF 2.0.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IVF 2.0

AI-Assisted Reproductive Technologyivf20.ai

IVF 2.0 is a UK-based AI software company that builds computer vision and predictive analytics tools — SiD for sperm selection and ERICA for embryo ranking — for IVF clinics. It serves fertility centers, with its flagship deployment at India's Gaudium IVF chain.

What IVF 2.0 does

IVF 2.0 is a UK-based, privately held embryology innovation organization founded in 2018 by internationally recognized embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. The company builds AI-driven software for fertility clinics, with two core products: SiD (Sperm Identification Device), which uses computer vision to analyze sperm samples and identify optimal cells for IVF procedures, and ERICA (Embryo Ranking Intelligent Classification Assistant), which applies predictive analytics to embryo imaging data to rank and classify embryos for embryologist decision support. Both systems are trained in part on Indian genome sequencing data to localize model precision for Indian patient populations. The company serves a single vertical — IVF clinics and fertility centers — and goes to market as a B2B technology provider rather than a direct-to-patient offering.

IVF 2.0's business model centers on technology licensing or integration with fertility clinic networks. In April 2026, the company entered the Indian market through a flagship partnership with Gaudium IVF and Women Health Ltd, integrating SiD and ERICA into clinical practice as India's first AI-driven infertility treatment program; the launch was inaugurated by Union Minister Nitin Jairam Gadkari. Early clinical observations from this deployment are reported as a 58% first-attempt clinical pregnancy success rate, up to 15% improvement in fertilisation and blastocyst development rates versus standard methods, and a potential 5–7% improvement in first-cycle IVF success rates. The India IVF market is projected to grow from USD 900 million in 2024 to USD 1.87 billion by 2029 at ~15.8% CAGR, providing the company's primary growth runway.

The company operates with 1–10 employees from London and has not publicly disclosed pricing, revenue, or funding rounds. Its near-term commercial profile is concentrated on a single named enterprise customer (Gaudium IVF), creating significant customer concentration risk. With two purpose-built AI products, a credible founder talent base, and a regionally differentiated data approach, IVF 2.0 sits in an early commercialization phase focused on establishing clinical validation and recurring clinic relationships in India before broader geographic or segment expansion.

IVF 2.0 firmographics

Firmographics
Name
IVF 2.0
Legal name
IVF 2.0
Website
https://ivf20.ai
Company type
Private
Founded year
2018
Headcount range
1–10 employees
Short description
IVF 2.0 is a UK-based AI software company that builds computer vision and predictive analytics tools — SiD for sperm selection and ERICA for embryo ranking — for IVF clinics. It serves fertility centers, with its flagship deployment at India's Gaudium IVF chain.
Ownership category
akta.pro rank

IVF 2.0 industry classification

Industry
Product category
AI-Assisted Reproductive Technology
NAICS
Software Publishers (5132), Computer Systems Design Services (541512)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYHDAEANAJ
AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)

Keywords

  • AI embryology tools
  • IVF success optimization
  • Embryo ranking software
  • Sperm identification systems
  • Fertility clinic AI

Where IVF 2.0 is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

IVF 2.0 business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

IVF 2.0 product offering

Product offering

Core offering

IVF 2.0 develops AI-driven embryology software for IVF clinics and fertility centers. Its two core products, SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), use computer vision and predictive analytics to optimize sperm selection and embryo ranking, with the aim of improving fertilisation, blastocyst development, and overall IVF success rates.

Product overview

IVF 2.0 is a UK-based embryology innovation organization founded by embryologists Dr. Jacques Cohen and Dr. Alejandro Chave, offering a portfolio of AI-driven embryology tools designed to improve IVF outcomes. The core offerings consist of two integrated AI systems: SiD (Sperm Identification Device) for sperm selection and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo ranking. These tools work together as part of a precision-led approach to infertility treatment, leveraging computer vision and predictive analytics to reduce the emotional and financial burden on patients while improving fertilisation and blastocyst development rates.

Differentiator

Problem solved

Functional benefit

Products and services

  • SiD (Sperm Identification Device) An AI-driven sperm identification system that uses computer vision to analyze and select optimal sperm cells for IVF procedures, designed to improve precision in infertility treatment and fertilisation outcomes for IVF clinics and embryologists.
  • ERICA (Embryo Ranking Intelligent Classification Assistant) An AI-powered embryo ranking platform that analyzes embryo visual characteristics and developmental potential to classify and rank embryos, helping clinicians select the most viable embryos for transfer and potentially increasing IVF success rates for fertility centers.

Quantifiable outcome

  • Up to 15% improvement in fertilisation and blastocyst development rates compared to standard methods
  • +2 more outcomes

Companies that use IVF 2.0

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

IVF 2.0 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

IVF 2.0 partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Gaudium IVF and Women Health LtdcoreTechnology or Integration · 1 April 2026IVF 2.0 partnered with Gaudium IVF to introduce AI-led embryology tools including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) into clinical practice. The initiative, inaugurated by Union Minister Nitin Jairam Gadkari, marks India's first AI-driven infertility treatment program. Early clinical observations indicate improved fertilisation rates and blastocyst development rates. The technology aims to improve outcomes while reducing emotional, physical, and financial burden on patients.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

IVF 2.0 competitors and assessment

Company assessment

Direct peers

  • Fairtility: Fairtility offers an AI-based embryo quality assessment platform (CHLOE) used by IVF clinics for transparent, data-driven embryo selection. It directly competes with IVF 2.0's ERICA in the AI embryo-ranking category.
  • Alife Health: Alife Health applies AI to fertility treatment decision support, including embryo selection and IVF cycle optimization. It is a direct peer addressing the same clinical pain points (sperm/embryo selection precision) with an AI software model.
  • Presagen: Presagen builds AI healthcare products with a focus on women's health and fertility, including embryo and oocyte assessment. It overlaps with IVF 2.0 in applying AI to reproductive medicine workflows.
  • AIVF: AIVF develops AI-based clinical decision support for IVF clinics, including embryo evaluation tools. It is the closest direct competitor to IVF 2.0's SiD and ERICA offerings, serving the same fertility clinic customer base with computer-vision-driven IVF optimization.
  • Life Whisperer (Vitrolife): Life Whisperer provides AI-based embryo and sperm viability assessment, now part of Vitrolife. It is a direct competitor to IVF 2.0 in AI-driven gamete and embryo selection.

Broad incumbents

  • Vitrolife: Vitrolife is a global provider of IVF media, consumables, and increasingly AI-enabled tools (via Life Whisperer). It is a broad incumbent in fertility whose portfolio overlaps with IVF 2.0's clinical decision support.
  • CooperSurgical (CooperCompanies): CooperSurgical is a major provider of fertility and women's health products, including IVF lab equipment and media. As a broad incumbent with deep clinic relationships, it represents both a competitive threat and a potential exit partner for IVF 2.0.
  • Genea Biomedx: Genea Biomedx develops IVF lab devices and software (e.g., Geri time-lapse incubator, Gems embryo culture). It is an incumbent in AI-enabled embryo monitoring and a relevant comparability anchor for IVF 2.0's clinical tooling.
  • Hamilton Thorne: Hamilton Thorne provides precision instruments, image-based systems, and AI/disposable products for the IVF and reproductive research markets. It is a broad incumbent whose imaging and analysis systems compete with IVF 2.0's computer-vision approach.

Emerging players

  • Univfy: Univfy uses predictive analytics to provide personalized IVF success probability reports, helping clinics with patient counseling. It is an emerging player in AI for IVF decision support with adjacent rather than direct overlap to IVF 2.0.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

IVF 2.0 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IVF 2.0 leadership team

Management profile

Number of profiles

Profiles2 records

IVF 2.0 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IVF 2.0 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IVF 2.0

What does IVF 2.0 do?

IVF 2.0 develops AI-driven embryology software for IVF clinics and fertility centers. Its two core products, SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), use computer vision and predictive analytics to optimize sperm selection and embryo ranking, with the aim of improving fertilisation, blastocyst development, and overall IVF success rates.

When was IVF 2.0 founded?

IVF 2.0 was founded in 2018. It employs 1 to 10 people.

Where is IVF 2.0 based?

IVF 2.0 is headquartered in London, United Kingdom, in the Europe region.

Who are IVF 2.0's main competitors?

Direct peers on record are Fairtility, Alife Health, Presagen, AIVF and Life Whisperer (Vitrolife). Broad incumbents are Vitrolife, CooperSurgical (CooperCompanies), Genea Biomedx and Hamilton Thorne. Univfy is listed as an emerging player.

Does IVF 2.0 have an API?

No public API is recorded for IVF 2.0.

What industry is IVF 2.0 in?

IVF 2.0's product category is AI-Assisted Reproductive Technology. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Prittle Prattle NewsGaudium IVF applies artificial intelligence to improve precision in infertility treatmentGaudium IVF has integrated artificial intelligence into infertility treatment in India, introducing AI-driven tools including SiD (a sperm identification system) and ERICA (an embryo ranking platform) into clinical practice. The initiative, inaugurated by Union Minister Nitin Jairam Gadkari, was developed in collaboration with UK-based embryology innovation organization IVF 2.0, with early observations indicating improved fertilisation rates and blastocyst development. Gaudium IVF, which recently became India’s first publicly listed IVF chain, aims to reduce the emotional and financial burden on patients through these precision-led AI tools.The HinduAI tools to increase IVF success rate and reduce patient costsGaudium IVF introduced two AI tools — SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) — developed by UK-based IVF 2.0, in New Delhi on April 1, 2026. The tools analyse samples across 2.5 million parameters to help embryologists select the best sperm and embryo, with early clinical observations suggesting improved fertilisation and blastocyst development rates. According to Dr. Manika Khanna, AI can increase first-cycle IVF success rates by 5–7% while reducing the emotional, physical, and financial burden on patients, with base IVF cycle prices starting at ₹2,00,000.Gadgets 360Fertility Clinic Chain Leads the Way With AI-Powered Infertility SolutionsGaudium IVF and Women Health Limited has introduced AI-led infertility treatment in India, deploying systems including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) to improve precision in IVF procedures. The company, which recently became India's first publicly listed IVF chain, partnered with AI tool suite IVF 2.0, founded by embryologists Jacques Cohen and Alejandro Chave, to integrate these technologies into clinical practice. Early clinical observations suggest the AI systems may improve fertilisation and blastocyst development rates, potentially reducing the need for repeat treatment cycles and easing emotional and financial burdens on patients.Express HealthcareGaudium IVF introduces AI-led infertility treatment, marking an industry first in IndiaGaudium IVF, India\'s first publicly listed IVF chain, has introduced AI-led infertility treatment integrating SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) systems, marking an industry first in the country. The AI technologies, developed in collaboration with UK-based embryology innovation organization IVF 2.0, are designed to enhance sperm selection and embryo ranking, with early clinical observations suggesting improved fertilisation and blastocyst development rates. Union Minister Nitin Jairam Gadkari inaugurated the initiative, highlighting India\'s growing strength in technology-led innovation across sectors.BW Healthcare WorldGaudium IVF Introduces AI-Led Infertility Treatment With Advanced Embryology SystemsGaudium IVF has introduced AI-led infertility treatment, integrating advanced AI-driven embryology systems including SiD and ERICA into routine clinical practice, one month after becoming India’s first publicly listed IVF chain. The systems were developed in partnership with UK-headquartered embryology innovation organization IVF 2.0, founded by embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. Union Minister Nitin Jairam Gadkari inaugurated the integration, emphasizing India’s growing strength in technology-driven innovation.WhalesbookGaudium IVF Launches India's First AI IVF Treatment for Better OutcomesGaudium IVF and Women Health Limited announced the launch of India's first AI-driven infertility treatment program, integrating ERICA and SiD AI systems developed by UK-based IVF 2.0 for embryo and sperm selection. The technology aims to improve fertilization and blastocyst development rates by up to 15% compared to standard methods, while reducing the emotional, physical, and financial burden on patients. India's IVF market is projected to grow from USD 900 million in 2024 to USD 1.87 billion by 2029, reflecting a CAGR of approximately 15.8%.